Neuraptive Therapeutics to Present Phase 2 NTX-001 Interim Results at 2024 ASSH Annual Meeting

Interim 24-week data from the NEUROFUSE study highlights the safety and efficacy of NTX-001 for peripheral nerve injuries.

CHESTERBROOK, Pa.--Neuraptive Therapeutics Inc., a prominent biopharmaceutical company specializing in treatments for peripheral nerve injuries, has announced interim topline results from its ongoing Phase 2 NEUROFUSE Study. These results will be showcased at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting, scheduled for September 19-21 in Minneapolis, MN. The presentation, titled "Safety and Efficacy of NTX-001 in the Treatment of Acute Single Transected Peripheral Nerve Injuries: A Phase 2 Randomized Controlled Trial," has been honored with a Top 10 Best Paper designation. Dr. David Brogan of Washington University will present these findings during the scientific paper session on Thursday, September 19.

The presentation will emphasize the interim findings from the 24-week analysis of the NEUROFUSE study, which assesses the safety and efficacy of NTX-001 in patients with acute, single-transected upper extremity peripheral nerve injuries. NTX-001 is a drug-device combination developed to enhance the speed and durability of functional recovery when used in conjunction with standard surgical repair. These interim results mark a significant milestone in the progression of NTX-001 as a new treatment option for peripheral nerve injuries.

Key findings at the 24-week mark include:
- NTX-001 showed significant improvement in Michigan Hand Outcomes Questionnaire (MHQ) total scores at both 8 and 24 weeks post-operation compared to the standard of care (SOC) alone.
- No safety concerns were identified with the use of NTX-001.
- At all evaluated time points, patients treated with NTX-001 reported significantly reduced post-operative pain compared to those treated with SOC alone.

These results highlight the potential of NTX-001 to boost functional recovery in patients with peripheral nerve injuries and justify further development of the treatment.

Dr. Brogan, lead author and primary investigator at Washington University in St. Louis, remarked, “Traumatic peripheral nerve transections remain a challenge in hand and upper extremity surgery. The potential application of PEG fusion to address this issue has garnered substantial interest among clinicians. The demonstrated improvements in pain and patient-reported outcomes signal an encouraging first step in meeting the needs of these patients.”

Evan Tzanis, Chief Operating Officer and Head of R&D at Neuraptive Therapeutics, Inc., stated, “We are excited to present these promising interim results from our Phase 2 trial of NTX-001 at such a pivotal scientific conference and look forward to sharing comprehensive study results at future conferences. We extend our gratitude to everyone involved in this study, including the investigators, clinical site staff, our team, and most importantly, the patients.”

About ASSH:
The American Society for Surgery of the Hand is the oldest medical society dedicated to hand and upper extremity surgery. Its mission is to advance the science and practice of hand and upper extremity surgery through education, research, and advocacy on behalf of patients and practitioners.

About Neuraptive Therapeutics, Inc.:
Neuraptive Therapeutics, Inc. is committed to the innovation and development of medical products and therapeutics aimed at repairing and regenerating peripheral nerves. The company focuses on addressing the unmet medical needs of patients and physicians dealing with the complex challenges of nerve injuries.